Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
lenalidomide
lenalidomide
Hazardous Drugs
Handling Guide (Group 2: Non-Antineoplastic)
* Non-Formulary
Brand names:
Revlimid
Form
Strength
CAPSULE, ORAL
5 mg; 15 mg
Last updated:
Dec. 19, 2022
Cell Status
NFISA
Black Box Warning:
Embryo-Fetal Toxicity and Restricted Distribution Program, Hematologic Toxicity, Venous Thromboembolism
FDA Drug Safety:
Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research for Revlimid (lenalidomide) Capsules
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier